On March 26, Ge Longhui Pharmaceutical Group (01110.HK) announced that for the year ended December 31, 2023, earnings increased by 12.6% to approximately RMB 1,079 million; profit attributable to company owners increased by 67.5% to approximately RMB 38.96 million, and basic profit per share increased 71.7% to approximately RMB 6.44 percent. The Board recommended a final dividend of HK3.38 cents per share.
During the year under review, the increase in the Group's earnings was mainly due to the increase in revenue from Kyoto Ninjian Honey Refined Kawakai Loquat Cream. The main reason for this increase is due to the increase in market demand during the year under review compared to 2022 due to the prevention and control of the epidemic and a better understanding of the epidemic. However, some of the medical equipment products manufactured for Dongdixin, including infrared thermometers, were offset by a decrease in sales. This type of epidemic prevention product will be in high demand in 2022.